• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

15.88 +0.17 (+1.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss ↗
August 06, 2026
Via Chartmill
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 06, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Gapping stocks in Friday's session ↗
July 31, 2026
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
July 31, 2026
Via Chartmill
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗
May 07, 2026
Via Chartmill
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
January 09, 2026
Via Stocktwits
News headline image
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? ↗
June 29, 2026
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
May 20, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 07, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
April 21, 2026
This biotech focused on precision medicines for cancer and immune disorders disclosed a notable insider sale after a strong year for shares. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
April 20, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
March 17, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
March 16, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
February 24, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
February 23, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗
February 05, 2026
Via MarketBeat
Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗
January 09, 2026
Via Stocktwits
Topics Government Stocks
News headline image
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
January 08, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
January 07, 2026
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 07, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
January 07, 2026
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
January 07, 2026
Via Chartmill
News headline image
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
January 07, 2026
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk. 
Via Stocktwits
Wednesday's pre-market session: top gainers and losers ↗
January 07, 2026
Via Chartmill
News headline image
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
January 07, 2026
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tuesday's after hours session: top gainers and losers ↗
January 06, 2026
Via Chartmill
News headline image
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
January 06, 2026
Conference call and webcast to be held at 8 a.m. ET on January 7, 2026 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap